Drug repositioning is the process of identifying novel therapeutic potentials for existing drugs and discovering therapies for untreated diseases. Drug repositioning, therefore, plays an important role in optimizing the pre-clinical process of developing novel drugs by saving time and cost compared to the traditional de novo drug discovery processes. Since drug repositioning relies on data for existing drugs and diseases the enormous growth of publicly available large-scale biological, biomedical, and electronic health-related data along with the high-performance computing capabilities have accelerated the development of computational drug repositioning approaches. Multidisciplinary researchers and scientists have carried out numerous attempts, with different degrees of efficiency and success, to computationally study the potential of repositioning drugs to identify alternative drug indications. This study reviews recent advancements in the field of computational drug repositioning. First, we highlight different drug repositioning strategies and provide an overview of frequently used resources. Second, we summarize computational approaches that are extensively used in drug repositioning studies. Third, we present different computing and experimental models to validate computational methods. Fourth, we address prospective opportunities, including a few target areas. Finally, we discuss challenges and limitations encountered in computational drug repositioning and conclude with an outline of further research directions.

Prediction is one of the most attractive aspects in data mining. Link prediction has recently attracted the attention of many researchers as an effective technique to be used in graph based models in general and in particular for social network analysis due to the recent popularity of the field. Link prediction helps to understand associations between nodes in social communities. Existing link prediction-related approaches described in the literature are limited to predict links that are anticipated to exist in the future. To the best of our knowledge, none of the previous works in this area has explored the prediction of links that could disappear in the future. We argue that the latter set of links are important to know about; they are at least equally important as and do complement the positive link prediction process in order to plan better for the future. In this paper, we propose a link prediction model which is capable of predicting both links that might exist and links that may disappear in the future. The model has been successfully applied in two different though very related domains, namely health care and gene expression networks. The former application concentrates on physicians and their interactions while the second application covers genes and their interactions. We have tested our model using different classifiers and the reported results are encouraging. Finally, we compare our approach with the internal links approach and we reached the conclusion that our approach performs very well in both bipartite and non-bipartite graphs.

No abstract

Background: The COVID-19 pandemic is suspected to have affected cancer care and outcomes among patients in Canada. In this study, we evaluated the impact of the state of emergency period during the COVID-19 pandemic (Mar. 17 to June 15, 2020) on cancer diagnoses, stage at diagnosis and 1-year survival in Alberta. Methods: We included new diagnoses of the 10 most prevalent cancer types from Jan. 1, 2018, to Dec. 31, 2020. We followed patients up to Dec. 31, 2021. We used interrupted time series analysis to examine the impact of the first COVID-19–related state of emergency in Alberta on the number of cancer diagnoses. We used multivariable Cox regression to compare 1-year survival of the patients who received a diagnosis during 2020 after the state of emergency with those who received a diagnosis during 2018 and 2019. We also performed stage-specific analyses. Results: We observed significant reductions in diagnoses of breast cancer (incidence rate ratio [IRR] 0.67, 95% confidence interval [CI] 0.59–0.76), prostate cancer (IRR 0.64, 95% CI 0.56–0.73) and colorectal cancer (IRR 0.64, 95% CI 0.56– 0.74) and melanoma (IRR 0.57, 95% CI 0.47–0.69) during the state of emergency period compared with the period before it. These decreases largely occurred among early-stage rather than late-stage diagnoses. Patients who received a diagnosis of colorectal cancer, non-Hodgkin lymphoma and uterine cancer in 2020 had lower 1-year survival than those diagnosed in 2018; no other cancer sites had lower survival. Interpretation: The results from our analyses suggest that health care disruptions during the COVID-19 pandemic in Alberta considerably affected cancer outcomes. Given that the largest impact was observed among early-stage cancers and those with organized screening programs, additional system capacity may be needed to mitigate future impact.

No abstract